Navigation Links
Research Supported by Samuel Waxman Cancer Research Foundation,Discovers Mode of Action of Arsenic-Based Drugs in Destroying,Cancer Cells

NEW YORK--(BUSINESS WIRE)--Apr 16, 2007 - Arsenic, a naturally occurring element, has been used in therapeutic compounds for over 2,000 years, and even now remains a venerable constituent of the traditional Chinese pharmacopeia.

Today, due in measure to the efforts of investigators supported by grants from the Samuel Waxman Cancer Research Foundation's (SWCRF) "Institute Without Walls," an arsenic derivative is being utilized in therapy for the treatment of certain types of acute leukemia.

In an important new development that holds promise for wider use of arsenic for treatment of other forms of cancer, the January 3, 2007 issue of the Journal of the National Cancer Institute published the results of research describing a new mode of action of arsenite (a form of the metal arsenic) in the treatment of acute promyelocytic leukemia (APL).

The research, conducted by Dr. Ethan Dmitrovsky, and his colleagues at Dartmouth Medical School, determined that arsenite selectively destroys APL cells. It was observed that arsenite causes a form of cell "suicide" in which digestive enzymes usually sequestered within the cancer cell are released into the cell at large.

Dr. Samuel Waxman, Founder and Scientific Director of SWCRF, notes "This discovery of a new mode of action of arsenic-based therapies establishes a new pathway that can lead to broader use of arsenic in developing therapies for treating other forms of cancer. It most certainly presents a new platform of knowledge that can stimulate new ideas that may ultimately increase the cure rate of APL to near 100%."

SWCRF provided grants supporting the research program led by Dr. Dmitrovsky, who is the Andrew G. Wallace Professor of Medicine and Pharmacology and Chairman, Pharmacology and Toxicology of Dartmouth Medical School, and also serves as Associate Scientific Director of SWCRF.

Arsenic and its derivatives are now part of the stand ard treatment for APL. Recent information indicates that the combination of the vitamin A derivative retinoic acid, arsenic and chemotherapy may cure over 90% of APL patients, which may result in extending the lives of an estimated 50,000 people a year.

About SWCRF

Now in its 32nd year, the Samuel Waxman Cancer Research Foundation (SWCRF) is a unique non-profit international organization dedicated to supporting focused concept-driven research to develop targeted cancer cell-specific therapies with minimal toxicity, such as differentiation therapy. Two drugs developed through Foundation-supported research, and now used worldwide, have proven the effectiveness of non-toxic differentiation in the treatment of acute promyelocytic leukemia (APL).

Since its inception, SWCRF has trained and supported more than 170 scientists with research grants exceeding $60 million. Based in New York City at The Mount Sinai Medical Center, the Foundation funds highly collaborative basic, translational and clinical research groups throughout the United States, Canada, China, Europe and Israel. SWCRF grant applicants are established investigators who agree to collaborate with other SWCRF investigators on all research projects funded by the Foundation.

Functioning as an "Institute Without Walls" the Foundation currently enables the collaboration of accomplished scientists in 28 different world-renown cancer research centers around the world. SWCRF hosts international conferences that bring together differentiation therapy investigators in a major forum to share their findings with the scientific community. Foundation-supported projects are reviewed and evaluated annually by an independent external committee of eminent scientists.

The Foundation derives most of its support from individual contributions. For the third consecutive year, Charity Navigator has awarded SWCRF its coveted four-star rating, indicating that the Foundation operates in the most fiscal ly responsible way possible to utilize its resources to attain its goal of a world without cancer.

For more information, visit www.waxmancancer.org.

Contact

Broadford & Maloney Inc.
Martin Maloney, 203-661-2900
m.maloney@bmcorp.com
or
Samuel Waxman Cancer Research Institute
Merle Duskin Kailas, 212-241-1760
mkailas@waxmancancer.org


'"/>




Related medicine technology :

1. NIEHS Researchers Identify Enzyme Critical in DNA Replication
2. Stanford Researchers Find Brain Pathway of Depression in Rats
3. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
4. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
5. Researchers Discover Method for Identifying How Cancer Evades the Immune System
6. Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos
7. Fact Sheet: Advancing Stem Cell Research While Respecting Moral Boundaries
8. President Bush Ignores Americas Plea for Support of Stem Cell Research
9. Researchers Discover Gene For Rare Skin Disorder
10. The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bushs Veto of the Stem Cell Research Enhancement Act
11. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017  Market Research Future published a ... Devices Market is expected to reach USD 33.6 million during the ... Market Highlights ... The Global Endoscopy Devices Market has been examined as a swiftly ... there is huge demand for endoscopy device in various regions.  The ...
(Date:1/17/2017)... YORK , Jan. 17, 2016  Attorney Advertising -- ... behalf of purchasers of Anthera Pharmaceuticals, Inc. ("Anthera" or the ... to obtain additional information and assist the investigation by visiting ... concerns whether Anthera and certain of its officers and/or directors ... Act of 1934. ...
(Date:1/17/2017)...  In a letter to President-elect Donald J. ... outlines AARP,s priorities for Americans age 50 and older ... affordable health care coverage, and lowering the cost of ... to President-elect Trump that "Our nearly 38 million members ... to protect their Medicare and Social Security benefits, protect ...
Breaking Medicine Technology:
(Date:1/17/2017)... Utah (PRWEB) , ... January 17, 2017 , ... ... of accredited, online continuing education for EMS and firefighting professionals, has released four ... (VILT) Solution. These new courses are taught live in an online classroom and ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... today announced its partnership with Sigfox in the U.S.A. to offer ... nationwide including new offerings on large-scale environmental sensor deployments such as monitoring ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley ... double blind clinical study for its dental gel that shows significant reduction in plaque ... toothpaste containing triclosan. The study was conducted at the Beckman Laser Institute at UC ...
(Date:1/17/2017)... York, NY (PRWEB) , ... January 17, 2017 ... ... Inc. Magazine’s fastest-growing private companies and ranked among the top US security companies ... Board of Directors. This announcement brings a year-long independent board nomination process ...
(Date:1/16/2017)... ... 17, 2017 , ... To provide comfort and fuel during ... fast-casual category, announces a hearty and wholesome Winter Menu. Starting today, guests can ... Sandwich, Cranberry Crunch & Honey Parfait, Slow Cooked Smoky Chicken & Sausage Soup, ...
Breaking Medicine News(10 mins):